β-blockers in coronary artery disease management

Hippokratia

Volumn 14, Issue 4, 2010, Pages 231-235

  Boudonas, G E ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

blockers; Acute coronary syndromes; Coronary artery disease; References; Review; Stable angina

Indexed keywords

ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOLYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NEBIVOLOL; NIFEDIPINE; NITRIC OXIDE; VERAPAMIL;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANGINA PECTORIS; ARTHRALGIA; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; BRONCHOSPASM; CORONARY ARTERY DISEASE; DRUG ACTIVITY; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG FATALITY; DRUG INDICATION; DRUG SAFETY; HEART HEMODYNAMICS; HEART INFARCTION; HEART MUSCLE INJURY; HEART REINFARCTION; HUMAN; HYPOTENSION; LOW DRUG DOSE; MORBIDITY; MORTALITY; MYALGIA; PREVALENCE; PURPURA; QUALITY OF LIFE; REVIEW; SHOCK; SIDE EFFECT; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS; SURVIVAL RATE;

EID: 78149396557     PISSN: 11084189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Frishman WH. Clinical pharmacology of the β-adrenoceptor blocking drugs, ed. 2. New York, Appleton-Century Crofts, 1984.
2. Manrique C, Giles TD, Ferdinand KC, Sowers JR. Realities of newer beta-blockers for the management of hypertension. J Clin Hypertens (Greenwich). 2009; 11: 369-375.
3. Kobusiak-Prokopowicz M, Jołda-Mydłowska B, Zubkiewicz A, Szymczak M, Mysiak A, Skalik R. Impact of nebivolol on levels of serum nitric oxide, plasma von Willebrand factor and exercise stress testing parameters in hypertensive and ischemic heart disease patients. Cardiol J. 2008; 15: 162-168.
4. The Norwegian Multicenter Study Group. Timolol induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med. 1981; 304: 801-807.
5. Brandler E, Paladino L, Sinert R. Does the early administration of beta-blockers improve the in-hospital mortality rate of patients admitted with acute coronary syndrome? Acad Emerg Med. 2010; 17: 1-10.
6. Cuculi F, Radovanovic D, Pedrazzini G, Regli M, Urban P, Stauffer JC, et al. Is pretreatment with Beta-blockers beneficial in patients with acute coronary syndrome? Cardiology. 2010; 115: 91-97.
7. Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. Circulation. 2008; 117: 296-329. Erratum in: Circulation. 2008 Feb 12;117:e162.
8. Roberts R, Rogers WJ, Mueller HS, Lambrew CT, Diver DJ, Smith HC, et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation. 1991; 83: 422-437.
9. van de Werf F, Janssens L, Brzostek T, Mortelmans L, Wackers FJ, Willems GM, et al. Short-term effects of early intravenous treatment with a beta-adrenergic blocking agent or a specific bradycardiac agent in patients with acute myocardial infarction receiving thrombolytic therapy. J Am Coll Cardiol. 1993; 22: 407-416.
10. Pfisterer M, Cox JL, Granger CB, Brener SJ, Naylor CD, Califf RM, et al. Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary Arteries. J Am Coll Cardiol. 1998; 32: 634-640.
11. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999; 318: 1730-1737.
12. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol. 2004; 44: e1e211.
13. Lopez-Sendon J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, et al. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J. 25: 2004; 1341-1362.
14. Hall SL, Lorenc T. Secondary prevention of coronary artery disease. Am Fam Physician. 2010; 8: 289-296.
15. Pajak A, Jankowski P, Kawecka-Jaszcz K, Surowiec S, Wolfshaut R, Loster M, et al. Changes in secondary prevention of coronary artery disease in the post-discharge period over the decade 1997-2007. Results of the Cracovian Program for Secondary Prevention of Ischaemic Heart Disease and Polish parts of the EUROASPIRE II and III surveys. Kardiol Pol. 2009; 67: 1353-1359.
16. Fornasini M, Yarzebski J, Chiriboga D, Lessard D, Spencer FA, Aurigemma P, et al. Contemporary trends in evidence-based treatment for acute myocardial infarction. Am J Med. 2010; 123: 166-172.
17. Aronow WS. Treatment after myocardial infarction. Compr Ther. 2007; 33: 39-47.
18. Yan AT, Yan RT, Tan M, Huynh T, Soghrati K, Brunner LJ, et al. Canadian ACS Registries Investigators. Optimal medical therapy at discharge in patients with acute coronary syndromes: temporal changes, characteristics, and 1-year outcome. Am Heart J. 2007; 154: 1108-1115.
19. Neumayr RH, Hauptman PJ. beta-Adrenergic receptor blockers and heart failure risk after myocardial infarction: a critical review. Curr Heart Fail Rep. 2009; 6: 220-228.
20. Duncker DJ, Boontje NM, Merkus D, Versteilen A, Krysiak J, Mearini G, et al. Prevention of myofilament dysfunction by beta-blocker therapy in postinfarct remodeling. Circ Heart Fail. 2009; 2: 233-242.
21. Ardissino D, Savonitto S, Egstrup K, Rasmussen K, Bae EA, Omland T, et al. Selection of medical treatment in stable angina pectoris: results of the International Multicenter Exercise Angina (IMAGE) Study. J Am Coll Cardiol. 1995; 25: 1516-1521.
22. Rehnqvist N, Hjemdahl P, Billing E, Björkander I, Eriksson SV, Forslund L, et al. Effects of metoporlol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (ASPIS). Eur Heart J. 1996; 17: 76-81.
23. Dargie HJ, Ford I, Fox KM. Total Ischaemic Barden European Trial (TIBET). Effects of ischaemia and treatment with atenolol nifedipin SR and their combination on outcome in patients with chronic angina. The TIBET Study Group. Eur Heart J. 1996; 17: 104-112.
24. Fox K, Garcia MA, Ardissino D, Buszman P, Camici PG, Crea F, et al. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J. 2006; 27: 1341-1381.
25. Vergoulas G. Antihypertensive agents and renal transplantation. Hippokratia. 2007;11: 3-12.
26. Bavry AA, Anderson RD, Gong Y, et al. Outcomes Among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil-SR/ Trandolapril STudy. Hypertension. 2010; 55: 48-53.
27. Antonakoudis G. Blood pressure control and cardiovascular risk reduction. Hippokratia. 2007;11: 114-119.